5th May 2005 16:45
AstraZeneca PLC05 May 2005 Dealing by DirectorsCompanies Act 1985 Sections 324/329 We hereby inform you that the interest of David R. Brennan, a Director of theCompany, in the American Depositary Shares (ADSs) of AstraZeneca PLC has changedas detailed below. One ADS equals one Ordinary Share. As previously notified on 31 March 2005, Mr Brennan became unconditionallyentitled to 18,925 ADSs on the partial vesting of an award under the terms ofthe AstraZeneca US Executive Performance Share Plan. Mr Brennan has elected todefer the value of those ADSs, less certain mandatory tax deductions, into theAstraZeneca US Executive Deferral Plan, a unitised stock fund established in2000, in which Mr Brennan, in common with other participating US executives, isdeemed to have a notional interest in ADSs calculated by reference to the fundvalue and the closing price of AstraZeneca ADSs. This deferral occurred on 29April 2005, following which Mr Brennan has a notional interest in 74,073 ADSs inthe AstraZeneca US Executive Deferral Plan as at 29 April 2005 based on thatday's closing price of US$43.95. In total, Mr Brennan now has an interest in 169,993 AstraZeneca ADSs, includingthe notional interest in ADSs in the AstraZeneca US Executive Deferral Planreferred to above. G H R MuskerCompany Secretary5 May 2005 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca